Written in Blood
Dr. Price and colleagues
reported on the multicenter,
randomized, controlled, phase
III RING (Resolving Infection in
Neutropenia with Granulocytes)
trial, which assessed the efficacy
of this therapy in patients with
neutropenia (defined as absolute
neutrophil count of <500/uL) and
proven or probable infection.
Patients were recruited from
14 transfusion medicine/hemostasis clinical trial network and
non-network sites. A total of 114
patients were randomized based
on risk status and type of infection to receive one of the following treatment regimens:
• Standard antimicrobial
therapy